匹伐他汀对HIV感染者冠状动脉疾病和炎症生物标志物的影响:REPRIEVE随机临床试验的机制子研究
这项REPRIEVE机制子研究纳入低至中等心血管风险的HIV感染者,随机接受匹伐他汀4mg/日或安慰剂治疗24个月。结果显示匹伐他汀减少非钙化冠状动脉斑块体积并延缓其进展,同时降低氧化低密度脂蛋白和脂蛋白相关磷脂酶A2水平,可能解释REPRIEVE中主要不良心血管事件减少的机制。
要点
- 匹伐他汀减少非钙化斑块体积并延缓其进展。
- 匹伐他汀降低氧化低密度脂蛋白和脂蛋白相关磷脂酶A2。
- 上述改变可能 contribute 于REPRIEVE中MACE减少。
核心结论
- 在低至中等心血管风险的HIV感染者中,匹伐他汀治疗24个月减少非钙化斑块体积和进展,并降低脂质氧化和动脉炎症标志物。
研究设计与样本
- 双盲、安慰剂对照随机临床试验,2015年4月至2018年2月在美国31个临床研究中心纳入正在接受抗逆转录病毒治疗、无已知心血管疾病且10年心血管风险低至中等的HIV感染者。
- 口服匹伐他汀钙4mg/日,主要结局为基线至24个月的非钙化冠状动脉斑块体积变化和进展。
主要发现
- 804例入组者中774例有至少1次可评估CTA,611例完成两次CT扫描并纳入斑块变化分析。
- 基线有斑块亚组效应更大(-8.8 mm3,95%CI -17.9至0.4)。
临床怎么用
- 对于低至中等心血管风险的HIV感染者,匹伐他汀4mg/日可能通过减少非钙化斑块和炎症标志物带来心血管获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cardiovascular disease (CVD) is increased in people with HIV (PWH) and is characterized by premature noncalcified coronary plaque. In the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), pitavastatin reduced major adverse cardiovascular events (MACE) by 35% over a median of 5.1 years. OBJECTIVE: To investigate the effects of pitavastatin on noncalcified coronary artery plaque by coronary computed tomography angiography (CTA) and on inflammatory biomarkers as potential mechanisms for MACE prevention. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled randomized clinical trial enrolled participants from April 2015 to February 2018 at 31 US clinical research sites. PWH without known CVD who were taking antiretroviral therapy and had low to moderate 10-year CVD risk were included. Data were analyzed from April to November 2023. INTERVENTION: Oral pitavastatin calcium, 4 mg per day. MAIN OUTCOMES AND MEASURES: Coronary CTA and inflammatory biomarkers at baseline and 24 months. The primary outcomes were change in noncalcified coronary plaque volume and progression of noncalcified plaque. RESULTS: Of 804 enrolled persons, 774 had at least 1 evaluable CTA. Plaque changes were assessed in 611 who completed both CT scans. Of 611 analyzed participants, 513 (84.0%) were male, the mean (SD) age was 51 (6) years, and the median (IQR) 10-year CVD risk was 4.5% (2.6-7.0). A total of 302 were included in the pitavastatin arm and 309 in the placebo arm. The mean noncalcified plaque volume decreased with pitavastatin compared with placebo (mean [SD] change, -1.7 [25.2] mm3 vs 2.6 [27.1] mm3; baseline adjusted difference, -4.3 mm3; 95% CI, -8.6 to -0.1; P = .04; 7% [95% CI, 1-12] greater reduction relative to placebo). A larger effect size was seen among the subgroup with plaque at baseline (-8.8 mm3 [95% CI, -17.9 to 0.4]). Progression of noncalcified plaque was 33% less likely with pitavastatin compared with placebo (relative risk, 0.67; 95% CI, 0.52-0.88; P = .003). Compared with placebo, the mean low-density lipoprotein cholesterol decreased with pitavastatin (mean change: pitavastatin, -28.5 mg/dL; 95% CI, -31.9 to -25.1; placebo, -0.8; 95% CI, -3.8 to 2.2). The pitavastatin arm had a reduction in both oxidized low-density lipoprotein (-29% [95% CI, -32 to -26] vs -13% [95% CI, -17 to -9]; P < .001) and lipoprotein-associated phospholipase A2 (-7% [95% CI, -11 to -4] vs 14% [95% CI, 10-18]; P < .001) compared with placebo at 24 months. CONCLUSIONS AND RELEVANCE: In PWH at low to moderate CVD risk, 24 months of pitavastatin reduced noncalcified plaque volume and progression as well as markers of lipid oxidation and arterial inflammation. These changes may contribute to the observed MACE reduction in REPRIEVE. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02344290.
引用
- Lu MT, Ribaudo H, Foldyna B, et al. Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial. JAMA Cardiol. 2024. PMID: 38381407. doi:10.1001/jamacardio.2023.5661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。